Meeting
2020 ASCO Virtual Scientific Program
EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors.
Authors
Justine Yang Bruce
Carbone Cancer Center, University of Wisconsin, Madison, WI
Justine Yang Bruce , Lajos Pusztai , Fadi S. Braiteh , Seema Rao Gorla , Chunzhang Wu , Joaquina Baranda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Immunoconjugates (non-IO)
Clinical Trial Registration Number
NCT04225117
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3647)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3647
Abstract #
TPS3647
Poster Bd #
377
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).
First Author: Anup Kasi
Poster
2023 ASCO Annual Meeting
A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.
First Author: Montaser F. Shaheen
